Effect of Cichorium intybus L. on the expression of hepatic NF‑κB and IKKβ and serum TNF‑α in STZ− and STZ+ niacinamide‑induced diabetes in rats by رضاقلی زاده, لطف اله et al.
Rezagholizadeh et al. Diabetol Metab Syndr  (2016) 8:11 
DOI 10.1186/s13098-016-0128-6
RESEARCH
Effect of Cichorium intybus L. on the 
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Abstract 
Background: Inflammation is an early event in the development of diabetes type 2 (T2D). Cichorium intybus L. 
(chicory) possesses anti-inflammatory action. We compared the anti-inflammatory aspect of aqueous chicory seed 
extract (CSE) in early and late stage T2D in rats.
Methods: Wistar albino rats were divided into nine final groups (n = 6). Three main groups consisted of non-diabetic 
(Control), early stage diabetes (ET2D; niacinamide/streptozotocin, i.e., NIA/STZ), and late stage diabetes (LT2D; STZ). 
Within each main group, a subgroup was treated with CSE (125 mg/kg; i.p.); within each diabetic group (STZ and NIA/
STZ) a subgroup received metformin (100 mg/kg; i.p.); another subgroup in STZ group received aspirin (120 mg/kg; 
oral). After 21 days, fasting blood glucose (FBS), insulin, and TNF-α level were measured in serum; IKKβ and NF-κB (p65) 
mRNA and protein expression were evaluated by real time PCR and Western blotting; p65 DNA binding activity was 
determined by ELISA, in liver tissue.
Results: The mRNA and protein expression levels of IKKβ, and P65 genes increased in both stages of T2D (p < 0.01); 
CSE decreased their expression (p < 0.001, mRNAs; p < 0.05, proteins). The increased DNA-binding capacity of NF-κB 
(p < 0.0001) in diabetes was lowered by CSE (p < 0.001). The effect of CSE was limited to ET2D requiring insulin.
Conclusions: The anti-inflammatory action of CSE is due to a direct modulation of cytokine expression. The depend-
ency of chicory action on the presence of insulin indicates its usefulness in the early stages of diabetes and for the 
purpose of preventing and delaying diabetes onset.
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Background
As a progressive disease, type 2 diabetes (T2D) may be 
divided into several stages based on the level of insulin 
in the serum. The “very early stage” of the disease, desig-
nated by us as VET2D, occurs when the beta cells show 
increased activity in an effort to compensate for the insu-
lin resistance within the peripheral, such as muscle and 
adipose, tissues, and so there is hyperinsulinemia. This 
may be considered as the silent stage of T2D because 
patients are asymptomatic and the fasting blood sugar 
(FBS) stays within normal range although bouts of hyper-
glycemia may occur during postprandial states.
Sessions of high blood sugar can exert toxic effects, 
glucotoxicity, on the beta cells of the pancreas and lead 
to the “early stage” diabetes, ET2D, when there is insuf-
ficient production of insulin due to partial beta cell 
destruction, and FBS test may show slightly above 
normal. Healthy diet and shunning overnutrition, by 
remodeling the body, and regular physical activity, by 
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sensitizing peripheral tissues toward insulin, can correct 
blood sugar levels at the onset of the disease. Drugs such 
as metformin and glibenclamide are used if diet changes 
and physical activity fail to lower blood sugar concentra-
tions to normal range.
“Late stage” diabetes, LT2D, will finally occur when a 
total destruction of the pancreatic beta cells leads to a 
complete cessation of insulin secretion and the patients 
become dependent on regular insulin injections in addi-
tion to metformin. Constant unchecked high blood sugar 
will lead to “very late stage” diabetes, VLT2D, when 
patients suffer from severe complications, such as blind-
ness, amputations, cardiovascular disease, renal compli-
cations, etc.
Major causes of insulin resistance are obesity and non-
resolving low grade chronic inflammation and infection 
[1, 2]. During inflammation, small proteins, known as 
inflammatory cytokines, are produced by different cell 
types and secreted into the circulation [3]. Elevated levels 
of circulating inflammatory cytokines, including nuclear 
factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) and tumor necrosis factor-alpha (TNF-α), in 
patients with postprandial hyperglycemia, may serve as 
predictors of the risk of type 2 diabetes [4].
Both TNF-α and NF-κB play important roles in insu-
lin resistance and β-cell dysfunction and contribute 
to the pathogenesis of T2D, and lipid disorders [5–7]. 
NF-κB has modulating effect on the synthesis of many 
cytokines, including TNF-α, IK-1β, Il-6 and Il-8, due to 
having NF-κB binding sites in the enhancer region of the 
corresponding genes. In turn, TNF-α and IL-1 are potent 
activators of NF-κB. Binding of NF-κB to the DNA at the 
genes of TNF-α and other cytokines establishes a positive 
auto-regulatory loop and leads to amplification of inflam-
matory response and longer duration of chronic inflam-
mation [8]. The ability of NF-κB to control multiple genes 
introduces the NF-κB signaling pathway as a potential 
drug target against inflammatory diseases [9].
Cichorium intybus L. (Chicory or Kasni) has been used 
in traditional medicine since the 17th century to treat 
digestive and hepatic disorders, as well as diabetes and 
inflammation. Modern research has been able to con-
firm the hypolipidemic, anti-oxidant, anti-inflammatory, 
atheroprotective, anti-hepatotoxic and antihyperglyce-
mic roles of chicory and to some degree elucidate the 
underlying mechanisms of action [10–16]. These diverse 
biological effects result from an array of medicinally 
important compounds, such as alkaloids, inulin, sesquit-
erpene lactones, coumarins, vitamins, chlorophyll pig-
ments, unsaturated sterols, flavonoids, saponins, tannins 
and polyphenols that are spread in all parts of the plant in 
different proportions [17]. Chicory, generally regarded as 
safe, has been implemented in several clinical trials with 
potential for delaying the onset of diabetes and man-
agement of osteoartheritis and cardiovascular disease 
[18–20].
Our studies with chicory have indicated its priority of 
use in early stages of diabetes when low amounts of insu-
lin are present [21]. As chicory has anti-inflammatory 
property, we aimed to investigate this aspect of CSE in 
ET2D and LT2D in rats. We used metformin and aspirin 
as control drugs and for purpose of comparison.
Aspirin and metformin are examples of plant sub-
stances that have been commercialized and available for 
many decades [22, 23]. Aspirin, well-known for its anti-
inflammatory effects, is used by over 60  % of diabetic 
patients for primary or secondary prevention of cardio-
vascular events [24, 25]. Metformin is the first-line phar-
macological therapy for T2D, which is prescribed for 
over 120 million people worldwide [26].
Methods
Reagents
Streptozotocin (STZ) and niacinamide also called nicoti-
namide (NIA) were purchased from Sigma (USA). Citrate 
buffer (20 mM, pH 4.5) was prepared manually and auto-
claved for sterilization. Bradford solution was prepared 
manually and filtered through Watman No 1 filter paper 
[27]. Metformin and aspirin pills (Chemidaru industrial 
company, Tehran, Iran) were purchased from a drug 
store. All other chemicals for Western blotting were ana-
lytical grade and from Sigma or Merck.
Animals
Healthy adult male 8-week old Wistar albino rats weigh-
ing 190–260 g, were obtained from University of Tehran, 
Institute of Biochemistry and Biophysics and housed in 
standard and clean cages (2 per cage) under controlled 
environmental conditions at room temperature 22 ± 2 °C 
and 12-hour light–dark cycle with free access to a stand-
ard rat chow and water. Animal handling and treatment 
were performed in the Biochemistry Department of the 
School of Medicine, of Tehran University of Medical Sci-
ences (TUMS). The study was ethically approved by the 
review board of TUMS.
Plant extract, metformin and aspirin
The lyophilized CSE powder belonged to a previous study 
[21]. Metformin and aspirin pills were crushed manually. 
Certain amounts (mg) of the lyophilized CSE (125 mg/kg 
b.w., according to previous studies [21, 28]), metformin 
and aspirin (100 and 120 mg/kg, respectively, according 
to Sun et  al. [29]) were weighed daily, in newly labeled 
Eppendorf vials, separately for each rat and according to 
weekly body weights measured by a digital balance (Sar-
torius, Germany). Citrate buffer (0.3  ml) was added, as 
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vehicle, to each vial and vortex mixed immediately before 
administration.
Diabetes induction
Early and late stage type 2 diabetes (ET2D and LT2D) 
were induced as previously explained [21]. Briefly, ET2D 
and LT2D were induced in overnight fasted rats by single 
intraperitoneal injections of streptozotocin (STZ, 55 mg/
kg) or combination of STZ (55 mg/kg) and niacinamide 
(NIA, 200 mg/kg, 15 min later), dissolved in citrate buffer 
(0.3  ml). In creating ET2D, it is possible to inject NIA 
15 min before or after STZ administration; in both occa-
sions, NIA exerts partial protection against β-cytotoxic 
effect of STZ and leads to creation of milder form of dia-
betes [30–32]. Elevated FBS in blood from the tail vein 
(GlucoSure STAR, Taiwan), on days 4 and 10, following 
injection of STZ or STZ +  NIA, was a confirmation of 
diabetes. FBS ranged between 140–220  mg/dl for the 
majority of rats on day 4 after injection of NIA+ STZ; 
therefore, rats were selected from among NIA  +  STZ-
injected rats for ET2D groups when FBS ranged between 
140–220  mg/dl on day 10 as well. FBS levels fell above 
300 mg/dl in most of the STZ-injected rats on day 4, and 
therefore, rats were selected from STZ-injected rats, for 
LT2D groups when FBS was greater than 300  mg/dl on 
both days 4 and 10. Only rats with stable diabetes were 
included in the study; a few rats from STZ/NIA group 
with very high FBS and rats from both STZ and NIA/
STZ groups, with normal FBS in the second occasion, 
day 10, were not included in the study. Normal rats, for 
the group Control, were injected with an equal volume of 
citrate buffer.
Experimental groups and treatment
After confirmation of diabetes on day 10, control and dia-
betic animals were divided into nine groups of at least six 
rats, and treated by an appropriate regimen for 21 days, 
as follows; the total study time being 31  days. CSE and 
metformin were administered via i.p. at a dosage of 125 
and 100 mg per kg body weight, respectively, suspended 
in 0.3  ml of citrate buffer. Aspirin, 120  mg per kg body 
weight, was given by gavage.
Control group Non-diabetic controls treated with cit-
rate buffer (0.3 ml).
CSE-control group Non-diabetic controls treated with 
chicory seed extract.
NIA/STZ group E-T2D rats treated with citrate buffer.
CSE-NIA/STZ group E-T2D rats treated with chicory 
seed extract.
Met-NIA/STZ group E-T2D groups treated with met-
formin.
STZ group L-T2D rats treated with citrate buffer.
CSE-STZ group L-T2D rats treated with chicory seed 
extract.
Met-STZ group L-T2D groups treated with metformin.
Asp-STZ group L-T2D groups that received aspirin.
Weekly measurements and sample collection
During 21 days of daily treatment, FBS was measured in 
a drop of blood from the tail for three successive weeks. 
Likewise, body weights were recorded weekly.
Sample collection
At the end of 21 day treatment time, the rats were trans-
ferred to metabolic cages at about 9 a.m. for 24 h urine 
collection with free access to water during this time; rat 
chow was removed at around 9 or 10 p.m. Without access 
to food until morning, the rats were in a state of fast-
ing before sacrifice. The next day, FBS was determined, 
in a drop of blood from the tail and rats were anaesthe-
tized with diethyl ether and blood samples collected by 
direct cardiac puncture; sera were separated and stored 
at −80 °C. The liver tissues were dissected, washed with 
cold phosphate buffer saline (PBS), submerged in liquid 
nitrogen, and stored in −80 °C. As we had only 8 meta-
bolic cages in our animal room, we could handle only 8 
animals per day, which we started with the animals with 
poorest health within the LT2D groups, continued with 
ET2D groups, and ended with controls.
Insulin determination
Serum, collected as above at the end of the study, was 
used to measure insulin by Insulin (rat) ELISA kit 
(Abnova).
Enzyme‑linked immunosorbent assay of serum TNF‑α
The measurement was performed by Tnf (rat) ELISA 
Kit according to the guidelines of the manufacturer 
(Abnova). Serum TNF-α was calculated according to a 
standard curve.
Real‑time PCR
Total RNA was extracted from liver tissue according 
to the manufacturer’s instructions (RNeasy Plus Mini 
Kit, Qiagen. Germany). Total RNA concentration was 
determined by spectrophotometric optical density 
measurement (NanoDrop 1000, Thermo Fisher Scien-
tific; USA) at 260 and 280  nm. Reverse transcriptase 
reactions were then carried out with 1 µg of total RNA 
using the First Strand cDNA synthesis Kit (Thermosci-
entific, USA). Real-time PCR was performed on cDNA 
samples using SYBR Premix PCR kit (Takara, Japan). 
Primers for P65 (Cat. No QT00381227) IKKβ (Cat. 
No QT00188622), and β-actin (Cat. No QT00193473) 
as a reference gene were predesigned by QuantiTect 
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Primer Assay (Qiagen, Germany). Samples were incu-
bated at 95 °C for 5 min for an initial denaturation, fol-
lowed by 40 cycles of denaturation at 95 °C for 5 s, and 
combined annealing and extension at 60 °C for 30 s. To 
confirm the amplification of specific transcript, melt-
ing curves were obtained at the end of each PCR run. 
The relative changes in gene expression were deter-
mined using CT and amplification of each sample. 
Real-time PCR was performed using Rotor-Gene Q 
(Qiagen, Germany).
Western blotting
Whole tissue extracts were obtained by gently crushing 
25 mg rat liver, for 1 min in a Potter–Elvehjem homog-
enizer (Thomas Scientific, Phila, USA), in 1  ml ice-
cold RIPA buffer (50  mM Tris, pH 7.4, 150  mM NaCl, 
5  mM EDTA, 1  % Triton X-100, 0.5  % sodium deoxy-
cholate, 0.1  % SDS, 1  mM PMSF and 1  mM sodium 
orthovanadate) containing protease and phosphatase 
inhibitor cocktail. Each homogenized sample was tritu-
rated through a clean sterile insulin syringe once and left 
on ice for 30  min before centrifugation at 12,000×g at 
4  °C for 20  min (Sigma 3–30  K). Some samples needed 
to be centrifuged a second time after careful collection 
and disposal of a fat layer on top. Proteins (60 µg, meas-
ured by Bradford method using BSA as standard) in 5× 
sample buffer were boiled for 5 min and resolved in 8 % 
SDS-PAGE, and immunoblotted (Mini Trans-Blot, Bio-
rad, USA) [27]. The membranes were blocked in Phos-
phate Buffered Saline with 0.05  % Tween-20 (PBST) 
containing 5 % nonfat dry milk (Merck) at 4 °C overnight. 
After washing with PBST, membranes were incubated 
for 2  h at 37  °C with polyclonal rabbit anti-p65 anti-
body (1:1000) and polyclonal rabbit anti-IKKβ antibody 
(1:500) (Abcam, USA). After washing with PBST, mem-
branes were incubated for 1 h at 37 °C with a horseradish 
peroxidase (HRP)-conjugated anti-rabbit IgG second-
ary antibody (1:20,000) (Abnova). The membranes were 
developed with the enhanced chemiluminescence (ECL) 
kit (Amersham Pharmacia Biotechnology). Protein levels 
were quantified by scanning densitometry using Image-J 
software.
NF‑κB (p65) DNA binding assay
DNA binding capacity of the NF-κB (p65) subunit in 
20 µg of cell lysates was determined using an NF-κB (p65) 
enzyme-linked immunosorbent assay (ELISA)-based 
transcription factor assay kit (Abnova, Taiwan), where a 
specific double stranded DNA (dsDNA) sequence con-
taining the NF-kB response element is immobilized onto 
the wells of a 96-well plate, according to the manufactur-
er’s protocol.
Statistical analysis
Statistical analysis was performed by SPSS software (ver-
sion 20). Normal distribution of continuous variables was 
checked by Kolmogrov-Smirnov test in each group. All 
variables in each group had normal distribution, so the 
comparison of continuous variables between different 
groups were carried out by one-way analysis of variance 
(ANOVA) followed by Scheffe and Dunnett T3 post hoc 
tests. For the changes of body weight and FBS values over 
time, within each rat group, comparison between time 
zero, day 10 and day 31, were performed by paired samples 
t test. Data were presented as the mean ± standard devia-
tion (SD). The level of significance was considered 0.05.
Results
Body weights and blood sugar after induction of diabetes
T2D was characterized by constant hyperglycemia and 
weight loss. Without intervention, blood sugar levels 
continued to rise and body weights continued to fall, 
as expected (Table 1). The extent of weight loss was not 
significant in NIA/STZ-induced diabetic groups. Fast-
ing blood glucose concentrations increased signifi-
cantly to >300 mg/dl in STZ groups (LT2D), and ranged 
between 140–220 mg/dl in NIA/STZ groups (ET2D). The 
first part of the present study appears similar to a previ-
ous study from our laboratory [21]. In both studies, rats 
were distributed in a wide range of body weights (190–
260 g). In the 2012 study, we distributed the rats in differ-
ent groups so to have similar average body weights in all 
groups which led to a wide standard deviation from the 
start. In the present study, however, we placed the rats 
with closest body weights in each group to obtain small 
standard deviations for the average weights. The rats 
with lowest body weight were assigned for Control. CSE 
was able to significantly lower FBS (p < 0.001) and cause 
an increase in body weight (p =  0.032) in ET2D rats in 
confirmation of our previous results (Table 1; Additional 
file 1) [21].
Insulin levels in serum
Serum insulin levels decreased about 70 % in NIA/STZ-
induced diabetes (p  =  0.001) and about 97  % in STZ-
induced diabetes (p < 0.001), compared with non-diabetic 
control rats. Although insulin levels were measured at the 
end of study time (day 31) we can still reasonably con-
clude that there was a significantly measurable amount 
of insulin in the NIA/STZ groups all through the study 
time and no insulin was present in the STZ groups (NIA/
STZ group vs. STZ group, p < 0.001). Therefore, we cat-
egorized the NIA/STZ-induced diabetes as ET2D, and 
the STZ-induced diabetes as LT2D. The status of fasting 
blood sugar and blood insulin are shown in Fig. 1a, b.
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TNF‑α in serum
TNF-α was elevated after diabetes induction (53  % 
in ET2D, p =  0.084; and 177 % in L-T2D, p < 0.001) as 
compared to controls. CSE and metformin did not sig-
nificantly lower the level of TNF-α (Fig.  2). Aspirin led 
to about 30 % decrease in serum TNF-α concentration in 
Asp-STZ group compared with STZ group (p =  0.003). 
While aspirin might be expected to improve TNF-α level 
in ET2D, not tested in this study, CSE certainly was una-
ble to lower TNF-α level in LT2D.
Protein and mRNA expression in liver
Real-time PCR and Western-blot analysis revealed 
low expression of IKKβ and NF-κB (p65) in the control 
groups (Control and CSE-control). After diabetes induc-
tion, the elevation in mRNA levels of both IKKβ and 
NF-κB (p65) genes was greater for LT2D (STZ-group) 
than ET2D (NIA/STZ group).
Treatment with CSE and metformin down-regulated 
the expression rates of mRNAs and proteins correspond-
ing to IKKβ and NF-κB (p65) in ET2D rats which was 
significant in case of CSE (CSE-NIA/STZ and Met-NIA/
STZ vs. NIA/STZ, p  <  0.01 and p =  0.06, respectively). 
The expression rate of mRNA and protein levels for IKKβ 
was lowered significantly by aspirin (Asp-STZ vs. STZ, 
p  <  0.01) whereas the p65 protein did not seem to be 
affected (Fig. 3). Western blot analysis on four members 
of each group is shown in Additional file  2.
DNA‑binding activity of P65 in liver
The DNA-binding activity of the NF-kB p65 factor 
strongly increased in the liver tissues of diabetic rats 
(NIA/STZ and STZ groups vs. Control, p < 0.001). Treat-
ment with CSE significantly decreased P65 DNA-bind-
ing activity (CSE-NIA/STZ vs. NIA/STZ, p  <  0.001). 
In ET2D, metformin did not improve the P65 DNA-
binding activity after 21  days, compared with NIA/STZ 
group. There were no significant changes in LT2D groups 
treated with CSE or metformin. Treatment with aspirin 
significantly decreased P65 DNA-binding activity (Asp-
STZ vs. STZ, p < 0.001) (Fig. 4).
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Fig. 1 Serum FBS (a) and insulin levels (b) at the end of study time 
(day 31). Serum insulin levels decreased significantly in NIA/STZ 
(p = 0.001) and STZ (p < 0.0001) diabetic groups relative to Control 
and CSE-control. Neither CSE nor metformin or aspirin treatment 
significantly improved serum levels of insulin in treated groups. The 
decrease by CSE of glucose levels in CSE-NIA/STZ group relative to 
NIA/STZ group, however, was marginally significant (p = 0.057). Data 
are presented as mean ± SD. It may be worth to mention that FBS 
levels in CSE-NIA/STZ group on day 31 was significantly lower com-
pared to day 10 (Table 1, p < 0.001)
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Fig. 2 Effect of CSE on TNF-α. Serum TNF-α levels increased signifi-
cantly in STZ group compared with Control and CSE-control. Aspirin 
decreased serum TNF-α in Asp-STZ group compared with STZ; 
*p < 0.001; ♦p < 0.001 versus controls. Values are mean ± SD of all 
subjects in each group
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Fig. 3 The expression levels of mRNA and protein for IKKβ, and NF-κB (p65) genes. The mRNA and protein expression levels for both genes were 
up-regulated in STZ and NIA/STZ groups relative to controls. CSE treatment led to down-regulation of the mRNA and protein levels of both genes 
in CSE-NIA/STZ group in comparison to NIA/STZ group. Metformin caused an insignificant decrease in Met-NIA/STZ (met-NIA/STZ vs. NIA/STZ: 
p = 0.22 and p = 0.06 for IKKβ mRNA and protein; p = 0.07 and p = 0.08 for p65 mRNA and protein, respectively). The mRNA levels of IKKβ, and 
p65 genes were effectively down-regulated in Asp-STZ compared to STZ; although aspirin significantly decreased the protein levels of IKKβ, it was 
not able to effectively lower the p65 protein level. *p < 0.01; ‡p < 0.05; †p < 0.001. ♣, ♦ and ♠ represent p < 0.01, p < 0.05 and p < 0.001, respec-
tively, versus non-diabetic controls. Dotted lines show comparisons between treated and their respective untreated groups. Data are expressed as 
mean ± SD of 3 duplicate experiments for real time. Four replicates were used for protein quantification
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Discussion
Despite a wide variety of oral hypoglycemic drugs, search 
for new herbs and nutraceuticals continues due to several 
limitations of existing drugs [33].
Plant extracts contain many small bioactive molecules 
with selective activities in natural proportions that can 
exhibit acute effects on many of the features of T2D, such 
as oxidative stress, inflammation, and hyperglycemia, by 
acting on multiple targets and via different mechanisms, 
simultaneously [34]. Some plant components have strong 
free radical scavenging capabilities that modulate oxida-
tive stress, others induce detoxification and antioxidant 
enzymes, and yet others have revealed to act via inhibi-
tion of signal-induced cytokine expression [35, 36].
The results show that inflammatory cytokines are 
upregulated in diabetes in both early and late stages; 
and suggest that CSE (125 mg/kg) is efficient in lowering 
blood sugar compared to metformin (100 mg/kg dosage) 
and aspirin (120 mg/kg) and that it possesses anti-inflam-
matory effect. For the second time we show that, inter-
estingly, CSE is effective only during ET2D and not LT2D 
stages and therefore, its effectiveness seems dependent 
on the presence of insulin.
Based on data in literature and our own experience, 
CSE may be acting through several mechanisms to lower 
inflammation in diabetic rats. First, as hyperglycemia 
can induce activation of NF-κB through advanced glyca-
tion end products [37], the anti-inflammatory effect of 
CSE may be secondary to glucose lowering effect, which 
might also explain to some degree the rationale behind 
the ineffectiveness of CSE in LT2D. We have previously 
determined that CSE is able to lower blood sugar in LT2D 
rats when insulin and CSE are given together; however, to 
help understand the insulin dependency of anti-inflam-
matory action of CSE, STZ and NIA/STZ rats treated 
with insulin and chicory should be provided in the future 
studies [38].
In line with previous reports, the findings suggest that 
the anti-inflammatory effect of CSE might be linked with 
reduced expression of proinflammatory cytokines, such 
as TNF-α and NF-κB, in ET2D rats [39]. TNF-α is pro-
duced in the early stages of inflammation and controls the 
production of other cytokines. It is expressed as a 26-kDa 
cell surface transmembrane protein that is cleaved to a 
17-kDa soluble form when activated [40]. Both the mem-
brane bound and the soluble forms of TNF-α can bind 
TNFR1 (TNF receptor type 1) and TNFR2 (TNF receptor 
type 2). After binding to its receptors, TNFα can lead to 
insulin resistance via inhibiting insulin receptor (IR) sign-
aling [7]. Therefore, less TNF-α would mean less contact 
with its receptors and more insulin sensitization. CSE did 
not significantly decrease TNF-α in serum in ET2D. It is 
not clear if longer duration of treatment would be able 
to show more significant TNF-α lowering effect, which 
could then be considered as the second mechanism.
Binding of TNF-α to its cell surface receptors can also 
lead to activation of canonical NF-κB pathway. In non-
stimulated cells, NF-κB dimers stay in the cytoplasm 
through interaction with inhibitory proteins, I kappa Bs 
(IκBs). After stimulation with proinflammatory cytokines 
such as TNF-α, the sequence of events in canonical 
NF-κB pathway involves rapid activation of multicompo-
nent protein kinase, the I kappa B kinase (IKK), leading 
to phosphorylation of two critical serines in the N-ter-
minal regulatory domain of IκBs, especially IκBα. Phos-
phorylated IκBα is recognized by a specific E3 ubiquitin 
ligase complex and undergoes polyubiquitination which 
targets it for rapid degradation by the 26S proteasome. 
NF-κB dimers, which are spared from degradation, trans-
locate to the nucleus to bind DNA and activate inducible 
expression of several genes [41]. Regulation of NF-κB 
activities by a range of endogenous and exogenous regu-
lators, including oxidants/antioxidants from plants, can 
occur via targeting any one of the above specific steps in 
the NF-κB pathway.
The results of the present study showed that the 
amount of IKKβ mRNA and protein increased in diabe-
tes and CSE was able to decrease the mRNA and pro-
tein levels   of IKKβ. Likewise, the amount of P65 that 
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Fig. 4 Effects of chicory extract on P65 DNA-binding activity. Liver 
tissue cell lysates with equal concentration of protein (20 µg; deter-
mined by Bradford) were used in this experiment. Optical density 
(OD) of samples was measured at 450 nm and OD changes was 
compared in all groups. P65 activity increased significantly in NIA/STZ 
and STZ groups compared with Control and CSE-control. Treatment 
with CSE significantly decreased P65 activity in CSE-NIA/STZ group 
compare with NIA/STZ group. Treatment with aspirin decreased it in 
Asp-STZ group when compared with STZ group. Metformin did not 
affect the P65 activity. Data are expressed as mean ± SD. *p < 0.0001; 
†p < 0.001; ♦p < 0.0001 versus Control
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represents NF-κB heterodimer increased in diabetic rats; 
CSE attenuated the expression of mRNA and protein of 
p65. Finally, the DNA-binding capacity of NF-κB which 
had increased in diabetes was also lowered by CSE.
Besides having direct effect on the expression of mRNA 
and protein of NF-κB (p65), CSE might have effects on 
each of the steps of the cascade, including phosphoryla-
tion, ubiquitination and degradation of IκBα, which we 
did not determine. However, by targeting the canoni-
cal NF-κB cascade at IKK at the upstream, CSE would 
be expected to bring about a partial reduction in all the 
steps of the cascade via reducing the amount of initial 
substrate for each step.
In addition to indirectly controlling the amount of 
NF-κB, and the cytoplasmic signaling events, phenolic 
antioxidant components of CSE may be capable of affect-
ing the functions of NF-κB in the nucleus. Some CSE 
components, such as caffeic acid, may directly inhibit 
binding of NF-κB with its DNA binding sequence [35] 
and other components capable of undergoing reduc-
tion–oxidation cycling may interfere by DNA binding 
of NF-κB indirectly; for example, via interacting with 
IRS-3 or targeting a redox sensitive protein factor in the 
nucleus [36, 42]. Inhibition of IκBα degradation, or an 
inhibition of DNA-binding via alkylation of p65 subu-
nit of IκBα, have also been suggested for CSE’s ability to 
inhibit NF-κB activation [43]. Targeting different steps of 
canonical NF-κB cascade can be categorized as the third 
mechanism of action.
We have previously determined that CSE acts as a 
PPARα activator [44]. Therefore, in addition to acting via 
its free radical scavenging elements, CSE may be able to 
inhibit the high glucose-induced production of cellular 
ROS by inhibiting NADPH oxidase activity [45]. Both 
aspirin and chicory are inhibitors of cyclooxygenase 1 
(COX-1) and COX-2 [23]. However, the inability of CSE 
to influence inflammatory markers in LT2D suggested a 
dependence of CSE’s anti-inflammatory activity on insu-
lin, or different mechanisms of action for aspirin and 
chicory.
Regarding the effects of metformin, it is well estab-
lished that metformin has evident anti-diabetic effects 
in T2D, both clinically and experimentally. In addition to 
anti-diabetic action, metformin seems to have other use-
ful properties as extending life span and acting against 
cancer. Metformin’s inability to reduce TNF-α in serum 
was in contrast with recent reports that measured TNF-α 
in isolated human monocytes and mice liver. How-
ever, higher dose of metformin (250 mg/kg) was used to 
reduce TNF-α levels in blood and liver of the mice [46], 
and the suppression of TNF-α production in human 
monocytes, depended on metformin concentration [47]. 
The quality and dose of metformin pill from Chemidaru 
Industrial Company was checked against metformin pill 
from Merck using HPLC, and was estimated to contain 
an average of 19.4 % ± 5.2 less metformin per pill (Addi-
tional file  3) [48]. As stated earlier, we chose the met-
formin dosage according to Sun et al. who found 100 mg/
kg metformin to be effective in lowering blood sugar in 
STZ-induced diabetic rats with hyperinsulinemia, labeled 
as VET2D by us [46]; but clearly the effect of metformin 
as an insulin sensitizer should depend on the stage of dia-
betes in terms of insulin levels in the body. In the pre-
sent study, the rats had ET2D, which is a more advanced 
stage of the disease with lower insulin levels and it may 
not be surprising that higher doses of metformin would 
probably be more effective. Therefore, the inability to see 
much effect for metformin, in this study, may be due to 
low dosage.
The mode of drug administration may play a role as 
well. In the present study, metformin and chicory extract 
were administered via intraperitoneal injection. As met-
formin exists in highest concentration in the portal vein, 
intestinal absorption may be the most convenient and 
proper way for metformin to access the liver and the gut, 
the main sites of action for metformin [26, 49].
Diet, weight control, physical activity, patient educa-
tion and pharmacological approaches, are ways to man-
age T2D. Our results show that in early stage diabetes 
(ET2D), where insulin secretion from pancreas is sig-
nificantly low, CSE performs better than metformin or 
aspirin in normalizing blood sugar; and better than met-
formin and as good as aspirin in reducing inflammation. 
Aspirin can possibly target the markers of inflammation 
in all stages of diabetes and probably in other inflam-
matory conditions, without major effect on blood sugar. 
CSE could not significantly improve any of the late stage 
diabetes conditions; however, if CSE’s mechanism of anti-
inflammatory and anti-hyperglycemic activities is medi-
ated by insulin, it may benefit patients with LT2D who 
inject insulin.
The role for insulin in enabling CSE to lower the mark-
ers of inflammation deserves more investigation. Failure 
of CSE, in the present study, to improve insulin levels in 
NIA/STZ animals was in agreement with the results of 
some studies [18, 28] and in contrast to others [21, 50]. 
Given that insulin levels fluctuate till stable manifestation 
of diabetes, an interim analysis of insulin in ET2D ani-
mals would have been informative to understanding the 
temporal effects of CSE, and a more definitive conclusion 
about whether or not CSE can stimulate more insulin 
secretion from the remaining beta cell of the pancreas.
The results stress on the importance of medical nutri-
tion therapy (MNT) in prevention of inflammation-based 
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diseases [51] and highlight the view that other than the 
dosage of medicines, that should be tailor-made for every 
patient, different medications may be required at differ-
ent stages of the disease.
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weight of each 500 mg pill: Merck, 516.63 mg; and Chemidaru, 582.50 mg. 
2.5, 5, 10, 50, and 100 mg of the powdered pills were dissolved in 1 ml of 
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